Navigation Links
Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Date:10/3/2007

WIXOM, Mich., Oct. 3 /PRNewswire-FirstCall/ -- Rockwell Medical Technologies, Inc. (Nasdaq: RMTI), a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on the end- stage-renal-disease market (ESRD), announced today that it has begun dosing patients in its Phase IIb Dose-Ranging Clinical Study for Soluble Ferric Pyrophosphate (SFP), the Company's physiological iron-maintenance-therapy drug.

The Phase IIb Clinical Design is a double-blind, multi-center, randomized, placebo-controlled, nine-month study consisting of up to 130 patients at multiple dialysis centers in the United States. The primary end points of the study are to evaluate SFP at varying dosage levels in hemodialysis patients and to determine the optimal concentration of SFP in dialysate that will maintain iron balance within their target hemoglobin range. Secondary end points include evaluating efficacy for changes in hemoglobin levels over time, reticulocyte hemoglobin content, incidence of systemic infection episodes and to quantify the amount of SFP iron transferred from the dialysate directly to the blood during the dialysis session.

Robert L. Chioini, Chairman and CEO of Rockwell stated, "Beginning the successful dosing of dialysis patients is another significant milestone in our clinical path for gaining FDA market approval for SFP. Going forward, we anticipate sharing news of our clinical progress as it becomes available."

About Soluble Ferric Pyrophosphate (SFP)

Rockwell's proprietary iron-delivery product, SFP, is a soluble form of iron designed to provide physiological iron- maintenance therapy in ESRD patients by delivering iron via dialysate during dialysis treatments. SFP
'/>"/>

SOURCE Rockwell Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... its public offering of 4,500,000 shares of its common stock ... per share. Aratana has granted the underwriters a ... 675,000 shares of its common stock. ...
(Date:9/17/2014)... Cardiac Dimensions ® , Inc. today announced ... II clinical trial of its enhanced CARILLON Mitral ... mitral regurgitation, functional improvement, quality of life and ... data, which was consistent with previous trials of ... 26 th annual Transcatheter Cardiovascular Therapeutics Conference ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
Breaking Medicine Technology:Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... Texas, Sept. 26, 2011 Vermillion, Inc. ... today announced the appointment of Donald Munroe, Ph.D. as ...  He will be responsible for furthering development of Vermillion,s ... continue the preclinical studies and initiate appropriate clinical studies ...
... SAN DIEGO, Sept. 26, 2011 Elevation Pharmaceuticals, Inc., ... aerosol therapies for patients with respiratory diseases, today announced ... and Chief Business Officer and Pravin Soni, PhD, as ... created positions. The company also announced that it drew ...
Cached Medicine Technology:Vermillion Enhances Management Team With A Key Addition 2Vermillion Enhances Management Team With A Key Addition 3Vermillion Enhances Management Team With A Key Addition 4Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives 2Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives 3
(Date:9/17/2014)... 17, 2014 (HealthDay News) -- A blood test that ... doctors with a better assessment of the state of ... If used routinely, this blood test could reveal when ... actually begins promoting tumor growth, the researchers suggested. ... patients with advanced prostate cancer and often initially very ...
(Date:9/17/2014)... this month for the November elections, one of the ... out the chamber door will be the Sustainable Growth ... of 2014. In a new commentary in the journal ... he and other advocates saw as the merits of ... Medicare pays doctors will return for the next Congress, ...
(Date:9/17/2014)... (PRWEB) September 18, 2014 Many countries ... influenza, instead of immunizations. The total number of poultry ... difficult to control, will result in huge losses. Therefore, ... avian influenza vaccines. , Avian influenza vaccines have been ... poultry farms in China began to use H5N1 avian ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Smart Flour ... Picks by Progressive Grocer, a leading trade magazine targeted ... awarded for originality and flavor, among other attributes. Smart ... an Editor’s Pick in the September print issue of ... website. , The pizza won based on its superior ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A petition ... ) in laparoscopic hysterectomies and other gynecological surgeries has ... to figures posted on Change.org, at least 84,908 supporters ... , According to a recent report from ABC News, ... by Dr. Hooman Noorchashm, after his wife, Dr. Amy ...
Breaking Medicine News(10 mins):Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4
... American Associations for Dental Research announced that its Journal ... Five-Year Scientific Impact Factor (SIF) from 4.195 to 4.389. In ... #1 in Article Influence. This news comes from the new ... Journal Citation Reports (JCR). This latest report also shows that ...
... researchers from Boston University School of Medicine (BUSM) and ... high rate of thyroid function testing in pregnant women. ... the Journal of Clinical Endocrinology & Metabolism , ... testing on pregnant women, approximately 80 percent of cases ...
... has discovered in young adult mice that a lone brain stem ... to specialized neurons and glia important types of brain cells ... new brain stem cells. A report on their study appears ... that the brain has the capacity to generate both neurons, which ...
... HealthDay Reporter , THURSDAY, June 30 (HealthDay News) -- The ... rooms for drinking-related injuries doubles over the July 4th weekend, ... sends a daily average of nearly 1,000 youth under 21 ... problems related to alcohol use, according to a report by ...
... Italy, 30 June 2011 Differences in male and female ... be more verbally fluent, have better manual dexterity and are ... the other hand often take less time parking their cars ... new city. The latter capacities, in which men tend to ...
... Insomnia is the most prevalent sleep disorder, affecting ... the United States on a weekly basis. ... ever, randomized, controlled clinical research study in the country ... Optimization is a non-invasive technology that helps the brain ...
Cached Medicine News:Health News:Journal of Dental Research increases its scientific impact factor 2Health News:BMC conducts high rates of thyroid testing in pregnant women, study finds 2Health News:Nervous system stem cells can replace themselves, give rise to variety of cell types, even amplify 2Health News:July 4 Weekend Dangerous for Underage Boys Who Drink: Report 2Health News:Sound localization at cocktail parties is easier for men 2Health News:Wake Forest Baptist conducts clinical study for insomnia using new technology 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: